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ORIGINAL ARTICLE
Isolated acute optic neuritis (AON) is an inflam-
matory or demyelinating disease of the optic nerve.
It may occur as an initial symptom of multiple
sclerosis (MS) or as an isolated, monosympto-
matic event.1,2 In demyelinating-related AON,
individuals aged 20–49 years are more at risk,
with females more often affected than males.3
The condition usually presents as a subacute loss
of vision, which can vary in severity from slight
deficit in the field of vision to complete loss of
light perception.4 The incidence is highest in
Caucasians,5 in countries at high altitude3 and in
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Methods: We retrospectively reviewed patients with AON who had received intravenous methylprednisolone
pulse therapy. These patients were classified into retrobulbar or papillitis groups. Demographic characteristics,
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these two groups.
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in the papillitis group and 58% in the retrobulbar group, p = 0.029). Two patients (8%) in the papillitis
group and six patients (32%) in the retrobulbar group developed multiple sclerosis (p = 0.061) with a mean
interval of 21.6 ± 11.2 months.
Conclusion: AON in Taiwan has a relatively lower percentage of development of multiple sclerosis than in
Western countries. The presence of periventricular plaque on MRI is significantly associated with the later
development of multiple sclerosis. The retrobulbar group had a stronger association with recurrence and
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spring.6 However, the incidence of AON in Asia is
not as high as in Western countries.7,8 Most of our
current knowledge on the condition and its man-
agement is based on the recommendations of the
Optic Neuritis Treatment Trial (ONTT).9 The sub-
jects enrolled in the ONTT were mainly Caucasians
(85%), and we do not know whether the results
are applicable to the population in Taiwan.
AON may be caused by other etiologies, such as
viral infection or autoimmune diseases, etc. This
subtype of AON has different clinical manifesta-
tions, age distribution and prognosis. In some in-
dividuals with AON, it is not easy to differentiate
idiopathic subtype from other etiologies during
an acute attack.
Intravenous methylprednisolone pulse therapy
has been suggested as a standard treatment by the
study results of the ONTT.9 Its advantage is that 
it can reduce the MS development rate during the
first 2–3 years of follow-up, although the difference
is insignificant by 10 years of follow-up between
treatment and placebo groups.10 There are few
retrospective studies in Taiwan.11,12
The aim of this study was to evaluate the dif-
ference between the papillitis type and retrobulbar
type in clinical manifestations, visual prognosis,
recurrence rate and development of MS in
Taiwanese patients with AON after intravenous
methylprednisolone pulse treatment.
Patients and Methods
We retrospectively investigated 73 patients between
January 1, 1991 and December 31, 2000 in the De-
partment of Ophthalmology, Kaohsiung Medical
University, who suffered from a first episode of
AON. Eligibility criteria for enrolment included the
following: (1) age range: 18–60 years inclusively;
(2) an acute or subacute clinical manifestation
consistent with optic neuritis4 with a duration of
visual symptoms of 10 days or less; (3) symptoms
occurring in both eyes within 1 week were assumed
to be bilateral; (4) positive relative afferent pap-
illary defect in unilateral patients; (5) abnormal
color vision in affected eyes; (6) a visual field 
defect in the affected eye. The major exclusion
criteria are listed in Table 1.
For each patient enrolled in this study, a de-
tailed history with regard to visual symptoms,
presence of initial ocular pain, and past history of
ocular, neurologic and systemic problems were
recorded. In addition, standardized ocular and
visual function examinations were performed, as
described below. Patient records with insufficient
data were also excluded from the study.
Visual acuity was measured subsequent to full
refractive correction using Landolt C chart at a
viewing distance of 5 meters, and the results of
decimal acuity were calculated as the logarithm
of the minimal angle of resolution (logMAR).
Color vision was tested using pseudoisochromatic
Ishihara plates (a total of 21 plates), with 21 con-
sidered normal color vision. The central 30° of
the visual field was evaluated by autoperimetry
using program 30-2 on a Humphrey field ana-
lyzer (Zeiss-Humphrey System, Dublin, CA, USA).
The methods for visual field classification were
similar to those used in the ONTT.13 Abnormal
visual fields were divided into seven categories:
diffuse depression, cecocentral scotoma, altitudi-
nal visual field defect, temporal wedge, nasal step,
enlarged blind spot, and arcuate scotoma.
Table 1. Major exclusion criteria for acute optic
neuritis
Treatment for optic neuritis already instituted
History consistent with optic neuritis receiving
corticosteroids
Corticosteroids already administered for systemic
conditions
Evidence of optic disc pallor in affected eyes
Ischemic optic neuropathy
Systemic disease as a predisposing factor of ischemic 
optic neuropathy (uncontrolled hypertension, 
moderate to severe heart disease, hyperlipidemia)
Present medication that could possibly give rise to 
retinal or optic nerve toxicity (e.g. ethambutol, 
phenothiazine)
Traumatic or compressive optic neuropathy (e.g. 
brain tumor)
Optic neuropathy of autoimmune or infectious cause
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Each patient underwent standardized neuro-
logic examination and ocular examination includ-
ing slit-lamp examination, fundoscopy, visual
evoked potential (VEP) test, and brain imaging
studies including magnetic resonance imaging
(MRI) or computed tomography (CT). In addition,
they accepted biochemical examination for com-
plete blood count (CBC), erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), venereal
disease research laboratory (VDRL), rheumatoid
factor (RhF) and antinuclear antibody (ANA).
All enrolled patients were divided into pa-
pillitis group or retrobulbar group according to
ophthalmoscopic findings. Each patient received
intravenous methylprednisolone (Solu-Medrol,
500 mg every 12 hours for 3 days) followed by
oral prednisolone (1 mg/kg of body weight/day),
which was tapered gradually according to the 
individual patient’s clinical manifestations. Demo-
graphic characteristics, clinical manifestations in-
cluding ocular and visual function examinations,
responsiveness to pulse therapy, and prognosis
were compared between the papillitis and retro-
bulbar groups. The diagnosis of MS was made by
neurologic specialists in our hospital. The diag-
nostic criteria for MS were based on the criteria
published by Poser et al14 for definite and proba-
ble MS. Recurrent optic neuritis was defined as new
attacks of optic neuritis which had an interval of
remission of at least greater than 4 weeks from
the previous attack.
The statistical analyses for recurrence rate and
positive rate of ocular manifestations and brain
imaging findings between these two subgroups
were analyzed using χ2 test. The analysis between
positive brain imaging findings and later devel-
opment of MS was performed using Fisher’s exact
test. The interval data such as mean age, follow-
up times and best-corrected visual acuity (BCVA)
between these two subgroups were analyzed using
Student’s t test. The level of statistically significant
difference used was p < 0.05.
Results
Characteristics of demographic and 
clinical manifestations
In this 10-year retrospective review, a total of 
73 patients were diagnosed with optic neuritis.
Seventeen patients were excluded owing to incom-
plete chart records or optic neuropathy of other
causes (listed in Table 1), 10 patients were excluded
owing to treatment other than pulse therapy and
another three patients were excluded owing to
age > 60 years or < 18 years. Finally, a total of 43
patients were enrolled in this study. Table 2 sum-
marizes the general and subgroup characteristics
of these patients. Mean age at onset was 34.8 ±
11.9 years, and 28 patients (65.1%) were female.
Bilateral optic neuritis was found in 13 of 43 pa-
tients (30.2%). Ocular or periocular pain, which
Table 2. Demographic and clinical characteristics of patients*
Total Retrobulbar group Papillitis group
Patients 43 19 (44.2) 24 (55.8)
Age at onset, yr 34.8 ± 11.9 32.1 ± 11.7 36.3 ± 12.1
Female 28 (65.1) 14 (73.7) 14 (58.3)
Bilaterality 13/43 (30.2) 6 (31.6) 7 (29.2)
Ocular pain 36/56 (64.3) 15/25 (60.0) 21/31 (67.7)
High ESR 8/32 (25.0) 5/15 (33.3) 3/17 (17.6)
High CRP 0/26 (0) 0/9 (0) 0/17 (0)
Abnormal ANA 0/28 (0) 0/14 (0) 0/14 (0)
Positive VDRL 0/31 (0) 0/16 (0) 0/15 (0)
Positive RhF 0/30 (0) 0/12 (0) 0/18 (0)
*Data are presented as n (%) or mean ± standard deviation. ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; ANA =
antinuclear antibody; VDRL = venereal disease research laboratory; RhF = rheumatoid factor.
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usually worsened with eye movement, was noted
in 64.3% of eyes. Based on ophthalmoscopic
findings, disc swelling (papillitis) was present in
24 patients (55.8%). ESR was mildly elevated in
eight of 32 patients (25%). In the retrobulbar
group, five of 15 patients had an elevated level of
ESR, and three of 17 patients in the papillitis
group had mild elevation of ESR. In addition, no
patient had positive VDRL, RhF or ANA.
Clinical characteristics of subgroups
Patients in the retrobulbar and papillitis groups
were compared based on age at onset, gender, 
bilaterality, ocular pain, and biochemical data.
Generally speaking, most parameters were similar
between the two groups. However, the percentage
of females was greater in the retrobulbar group
(73.7%) than in the papillitis group (58.3%).
The mean age at onset in the retrobulbar group
(32.1 ± 11.7 years) had a tendency to be younger
than that in the papillitis group (36 ± 12.1 years).
However, neither of the two results was statistically
significant. Table 2 summarizes the characteristics
in these two subgroups.
Visual function of affected eyes
Visual acuity was measured in all patients by
Landolt C chart on admission. The average BCVA
was 1.47 ± 1.20 logMAR. If BCVA by Landolt C of
less than 0.1 is defined as poor, then there were
29 eyes (51.8%) in the poor group. If visual acuity
was rated as relatively good when it was 0.5 or
better, then there were 11 eyes (19.6%) in the
better group (Figure). Autoperimetry was per-
formed on 50 eyes. All results were judged ab-
normal. The most common type of visual field
defect was diffused depression, which accounted
for 44% of all cases. Table 3 summarizes the types
of visual field abnormality. Thirty-four patients
accepted VEP tests; all showed abnormalities in-
cluding decreased amplitude and delay of latency
of P100 in affected eyes.
Prognosis of subgroups
All 43 patients received intravenous pulse therapy
with methylprednisolone as the initial treatment,
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Figure. Distribution of best corrected visual acuity (BCVA)
by Landolt C of affected eyes at onset of acute optic neuritis.
Twenty-five eyes were in the retrobulbar group and 31 eyes
were in the papillitis group. BCVA < 0.1 was found in 29
out of a total of 56 eyes (51.8%). There were only 11 eyes
(19.6%) with BCVA of 0.5 or better.
Table 3. Types of visual field abnormality*
Type of abnormality Total Retrobulbar Papillitis
Diffuse depression 22 (44.0) 11 (52.4) 11 (37.9)
Cecocentral scotoma 9 (18.0) 3 (14.3) 6 (20.7)
Altitudinal visual field defect 5 (10.0) 2 (9.5) 3 (10.3)
Nasal step 5 (10.0) 2 (9.5) 3 (10.3)
Temporal wedge 4 (8.0) 1 (4.8) 3 (10.3)
Enlarged blind spot 4 (8.0) 2 (9.5) 2 (6.9)
Arcuate scotoma 1 (2.0) 0 1 (3.6)
Total 50 21 29
*Data are presented as n (%).
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followed by oral prednisolone, which was tapered
gradually according to the individual patient’s
clinical manifestations. Mean treatment time was
37.2 ± 13.7 days, and there was no significant dif-
ference between the retrobulbar and papillitis
groups (37.6 ± 14.6 days vs. 36.8 ± 13.4 days,
p = 0.854). After treatment, the visual acuity in
both groups showed a significant improvement.
There were no significant differences between the
retrobulbar and papillitis groups in recovery time
(43.9 ± 16.2 days vs. 47.1 ± 15.7 days, p = 0.573)
or BCVA after recovery (0.51 ± 0.95 logMAR vs.
0.32 ± 0.57 logMAR, p = 0.353). Initial BCVA had
no positive or negative correlation with final
BCVA. On brain imaging studies, both groups
showed a similar percentage of optic nerve swell-
ing (47.4% in the retrobulbar group, 50% in the
papillitis group, p = 0.864). However, the positive
rate of periventricular plaque shown on brain
MRI in the retrobulbar group was higher than in
the papillitis group, but it was not statistically
significant (27.8% vs. 9.1%, p = 0.130). Eleven
patients (57.9%) in the retrobulbar group and
five patients (20.8%) in the papillitis group had
at least one new episode of optic neuritis with
mean intervals of 25.1 ± 25 months and 29.8 ±
17.9 months, respectively. The recurrence rate of
optic neuritis in the retrobulbar group was sig-
nificantly higher than that in the papillitis group
(p=0.029). During follow-up, six patients (31.6%)
in the retrobulbar group developed definite or
probable MS compared with only two patients
(8.3%) with newly diagnosed MS in the papilli-
tis group (p = 0.061). In the correlation between
imaging findings and later development of MS,
among the seven patients with positive brain
MRI findings, five (71.4%) developed definite or
probable MS during the follow-up period (p =
0.002). However, among the 22 patients with
optic nerve swelling found by initial imaging
studies, there were only five patients (22.7%) who
later developed MS (p = 0.457). Table 4 summa-
rizes the clinical course and prognosis in these
two subgroups.
Discussion
With regard to the demographic characteristics
of our Taiwanese patients, the mean age at onset
was 34.8 years and 65.1% of patients were female.
From the ONTT report, 77% of patients were fe-
male with a mean age of 31.7 years.5 In Wakakura
et al’s study of the Japanese population, most 
patients were female (69%), and the mean age at
onset was 36.3 years.15 Our overall data are simi-
lar to the results of Wakakura et al. But in the
retrobulbar type, our data are quite similar to the
ONTT report (mean age, 32.1 years; female,
73.7%).4,5
Table 4. Clinical course and prognosis*
Retrobulbar group Papillitis group p
Follow-up (mo) 59 ± 21.9 63.8 ± 21.8 0.532
Duration of treatment (d) 37.6 ± 14.6 36.8 ± 13.4 0.855
Duration of recovery (d) 43.9 ± 16.2 47.1 ± 15.7 0.573
BCVA at onset (logMAR) 1.34 ± 1.23 1.58 ± 1.18 0.470
BCVA after recovery (logMAR) 0.51 ± 0.95 0.32 ± 0.57 0.353
Improvement on BCVA (line) 6.7 ± 3.8 7.0 ± 4.1 0.720
Periventricular plaque 5/18 (27.8) 2/22 (9.1) 0.130
Optic nerve swelling 9/19 (47.4) 12/24 (50.0) 0.864
Recurrent rate† 11/19 (57.9) 5/24 (20.8) 0.029
Interval of recurrence (mo) 25.1 ± 25.0 29.8 ± 17.9 0.265
Development of MS 6/19 (31.6) 2/24 (8.3) 0.061
Interval of MS (mo) 21.3 ± 11.2 22.5 ± 10.6 0.902
*Data are presented as n (%) or mean ± standard deviation; †p < 0.05. BCVA = best-corrected visual acuity; MS = multiple sclerosis.
Prognosis of isolated optic neuritis
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With regard to the imaging findings, brain MRI
is a very important tool in the diagnosis of MS.16
According to reports from the ONTT, the presence
of signal abnormalities on brain MRI performed
at the time of optic neuritis was the single most
important predictor of the development of clini-
cally definite MS by 5 years.17 The 10-year risk of
MS is strongly associated with the presence of
one or more lesions on the baseline brain MRI.18
In our study, the presence of periventricular plaque
on MRI at the first AON attack was also signifi-
cantly associated with the later development of
MS, but we did not find a significant association
between optic nerve swelling and later develop-
ment of MS.
In Western countries, retrobulbar neuritis is the
most common type of optic neuritis in adults.5,10,19
From the ONTT report, 64.7% belonged to the
retrobulbar type.10 In our study, 19 of 43 patients
(44.2%) had the retrobulbar type. Comparing
with data from Asian countries: Wakakura et al
reported an incidence of 50% for the retrobulbar
type in Japanese,15 Bee et al11 and Lin et al12 re-
ported an incidence of 44.4% and 46.8%, respec-
tively, for the retrobulbar type in Taiwanese, and
Wang et al8 reported a much lower incidence of
35% for the retrobulbar type in Singapore.
With regard to prognosis, there were no obvi-
ous differences in mean follow-up time, duration
of treatment/recovery, improvement in visual acu-
ity or interval of recurrence between the retrobul-
bar and papillitis groups. However, our present
study demonstrated several important differences
between these two groups. First, the recurrence rate
of AON in either eye was higher in the retrobulbar
group (57.9% vs. 20.8%, p = 0.029). Second, in the
retrobulbar group, six of 19 patients developed
newly diagnosed MS; the incidence was higher
than that in the papillitis group, but it was not
statistically significant (31.6% vs. 8.3%, p = 0.061).
Disc swelling is a nonspecific finding in optic
neuritis, and it is not very useful in distinguish-
ing demyelinating optic neuritis from the optic
neuritis that may accompany other inflammatory
or infectious diseases, such as virus infection,
syphilis, sarcoidosis, or Lyme disease, etc.20 Kahana
et al19 reported that MS was more likely to develop
in optic neuritis patients with a normal disc (60%
of 30 patients) than in those with a swollen disc
(13% of 45 patients) within an average follow-
up of 9.5 years. Similar results were found in the
ONTT study, which stated that the risk of MS is
lower when the optic disc is swollen compared
to when it is not swollen. Our study showed the
same situation, though the difference was not
statistically significant.
Compared with the ONTT and other study
groups in Asia, the demographic characteristics
of patients with AON showed several differences
among these study groups (Table 5). In the ONTT
group, 77.2% of patients were female with an aver-
age age of 31.8 years.5 Among our and Wakakura’s
et al15 study groups in Asia, the percentage of 
females was relatively lower, accounting for approx-
imately two-thirds of AON patients. Most sur-
prisingly, from Wang et al’s group in Singapore,8
males were affected more commonly than females
by a ratio of 3:2. Regarding mean age at onset,
Table 5. Comparison of optic neuritis with other study groups
Present Lin et al12 Wakakura et al15 Wang et al8 ONTT5,10
study (Taiwan) (Japan) (Singapore) (USA)
Female, % 65.1 53.2 69.0 40.0 77.2
Mean age, yr 34.8 41.2 36.3 40.0 31.8
Disc swelling, % 55.8 53.2 50.0 65.4 35.3
Ocular pain, % 64.3 56.3 56.0 50.0 92.2
Periventricular plaque, % 16.7 34.9 14.0 4.5 49.0
Development of MS, % 18.6 14.7 N/A N/A 36.0
MS = multiple sclerosis.
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AON patients in Asia were relatively older than
those in the ONTT group. In terms of clinical
manifestation, the incidence of disc swelling in
affected eyes was relatively higher in Asian pa-
tients (from 50% to 65.4%) than in ONTT patients
(35.3%). In addition to the race factor, the different
results among the reports in Asia were partly caused
by differences in inclusion criteria, especially as
most of the studies were done retrospectively.
Therefore, before a multicentered prospective trial
is performed to answer these questions, we should
be very careful to interpret the differences. Ocular
motility associated pain was observed in 92.2%
of the ONTT group, whereas it was detected less
commonly in Asian patients (50% in Wang et al’s
report8 to 64.3% in our present study). In con-
trast to the 49% of patients with periventricular
plaque found on brain MRI in the ONTT group,
there was a significantly lower positive rate of
periventricular plaque in the Asian studies (4.5%
in Wang et al’s report8 to 34.9% in Lin et al’s 
report12). The incidence of MS after the onset of
AON ranged from 14.7% in Lin et al’s report12 to
18.6% in our present study, which was relatively
lower than the ONTT group (36%).10 Based on
Western studies, the incidence of MS after AON
ranges from 36% to 85% according to different
follow-up periods.21–23 However, the majority of
Asian patients with AON are less likely to develop
MS. Epidemiologic findings have also implicated
a genetic influence on the development of MS.
The Asian population has a much lower prevalence
rate for MS compared to the American white pop-
ulation regardless of the altitude24 or region,25,26
as may also be said for optic neuritis. The higher
percentage of disc swelling in our study could be
one of the reasons for the lower incidence of MS
in Taiwan.
The shortcomings of this study are that it was
a retrospective study, some of the cases might be
omitted due to insufficient records; in some pa-
tients, it was also difficult to separate cases of AON
of demyelinating cause from other causes just
based on the clinical manifestations and labora-
tory tests. There must exist some overlap between
the retrobulbar and papillitis subtypes of AON.
Therefore, a well-designed, multicentered cooper-
ative and prospective study is necessary to clarify
the issue.
In summary, in our study of Taiwanese patients,
the finding of periventricular plaque on brain MRI
at the initial stage of AON was significantly asso-
ciated with the later development of MS following
AON. In the comparison of subgroups, the mean
age at onset in the retrobulbar group had a ten-
dency to be younger than in the papillitis group.
During the mean follow-up of > 5 years, the
retrobulbar group had a stronger association with
a higher recurrence rate. Although not reaching
statistical significance, the retrobulbar type has a
greater chance for the later development of MS.
Moreover, though less frequent, papillitis patients
still have the possibility of developing MS in
long-term follow-up.
References
1. Eber GC. Optic neuritis and multiple sclerosis. Arch Neurol
1985;42:702–4.
2. Rolak LA, Beck RW, Paty DW, et al; Optic Neuritis Study
Group. Cerebrospinal fluid in acute optic neuritis: experience
of the optic neuritis treatment trial. Neurology 1996;46:
368–72.
3. Jin YP, de Pedro-Cuesta J, Soderstrom M, et al. Incidence
of optic neuritis in Stockholm, Sweden 1990–1995, I: age,
sex, birth and ethnic-group related patterns. J Neurol Sci
1998;159:107–14.
4. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized,
controlled trial of corticosteroids in the treatment of acute
optic neuritis. N Engl J Med 1992;326:581–8.
5. Optic Neuritis Study Group. The clinical profile of optic
neuritis: experience of the optic neuritis treatment trial.
Arch Ophthalmol 1991;109:1673–8.
6. Jin YP, de Pedro-Cuesta J, Soderstrom M, et al. Incidence
of optic neuritis in Stockholm, Sweden 1990–1995, II: time
and space patterns. Arch Neurol 1999;56:975–80.
7. Barlow JS. Multiple sclerosis in North Korea and China.
Neurology 1967;17:802.
8. Wang JC, Tow S, Aung T, et al. The presentation, aetiology,
management and outcome of optic neuritis in an Asian
population. Clin Exp Ophthalmol 2001;29:312–5.
9. Beck RW, Trobe JD. What we have learned from the optic
neuritis treatment trial. Ophthalmology 1995;102:1504–8.
10. Optic Neuritis Study Group. The optic neuritis treatment
trial: three-year follow-up results. Arch Ophthalmol 1995;
113:136–7.
Prognosis of isolated optic neuritis
J Formos Med Assoc | 2007 • Vol 106 • No 8 663
11. Bee YS, Lin MC, Wang CC, et al. Optic neuritis: clinical
analysis of 27 cases. Kaohsiung J Med Sci 2003;19:
105–11.
12. Lin YC, Yen MY, Hsu WM, et al. Low conversion rate to
multiple sclerosis in idiopathic optic neuritis patients in
Taiwan. Jpn J Ophthalmol 2006;50:170–5.
13. Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual
field profile of optic neuritis. The experience of the optic
neuritis treatment trial. Arch Ophthalmol 1993;111:
231–4.
14. Poser CM, Paty DW, Scheiberg L. New diagnostic criteria
for multiple sclerosis: guidelines for research protocols.
Ann Neurol 1983;13:227–31.
15. Wakakura M, Minei-Higa R, Oono S, et al. Baseline 
features of idiopathic optic neuritis as determined by a
multicenter treatment trial in Japan. Jpn J Ophthalmol
1999;43:127–32.
16. Kanski JJ. Neuro-ophthalmology. In: Kanski JJ, ed. 
Clinical Ophthalmology, 4th edition. Oxford: Butterworth-
Heinemann, 1999:590–2.
17. Optic Neuritis Study Group. The 5-year risk of MS after
optic neuritis. Neurol 1997;49:1404–12.
18. Optic Neuritis Study Group. High and low-risk profiles 
for the development of multiple sclerosis within 10 years
after optic neuritis. Arch Ophthalmol 2003;121:944–9.
19. Kahana E, Alter M, Feldman S. Optic neuritis in relation to
multiple sclerosis. J Neurol 1976;213:87–95.
20. Miller NR, Newman NJ. Multiple sclerosis and related 
demyelinating disease. In: Newman NJ, ed. Clinical Neuro-
Ophthalmology, 5th edition. Pennsylvania: Williams &
Wilkins, 1997:5539–76.
21. Francis DA, Compston DAS, Batchelor JR, et al. A reassess-
ment of the risk of multiple sclerosis developing in patients
with optic neuritis after extended follow-up. J Neurol 
Neurosurg Psychiatry 1987;50:758–65.
22. Sandberg-Wollheim M, Rynke H, Cronqvist S, et al. A long-
term prospective study of optic neuritis: evaluation of risk
factors. Ann Neurol 1990;27:386–93.
23. Rodriquez M, Siva A, Cross SA, et al. Optic neuritis: a
population-based study in Olmsted County, Minnesota.
Neurology 1995;45:244–50.
24. Fritch JA, McLeod JG, Hely M. Acute optic neuritis in
Australia: a 13 year prospective study. J Neurol Neurosurg
Psychiatry 2000;68:246–51.
25. Sergott RC, Brown MJ. Current concepts of the pathogenesis
of optic neuritis associated with multiple sclerosis. Surv
Ophthalmol 1988;33:108–16.
26. Shibasaki H, Okihiro MM, Kuroiwa Y. Multiple sclerosis
among Orientals and Caucasians in Hawaii: a reappraisal.
Neurology 1978;28:113–8.
